Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Enterprise Value (2016 - 2025)

Agios Pharmaceuticals' Enterprise Value history spans 14 years, with the latest figure at -$854.4 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 4.4% year-over-year to -$854.4 million; the TTM value through Dec 2025 reached -$854.4 million, up 4.4%, while the annual FY2025 figure was -$854.4 million, 4.4% up from the prior year.
  • Enterprise Value reached -$854.4 million in Q4 2025 per AGIO's latest filing, up from -$952.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$569.9 million in Q2 2024 to a low of -$2.3 billion in Q1 2021.
  • Average Enterprise Value over 5 years is -$956.0 million, with a median of -$873.9 million recorded in 2025.
  • Peak YoY movement for Enterprise Value: crashed 341.83% in 2021, then soared 60.46% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$1.0 billion in 2021, then grew by 23.22% to -$783.1 million in 2022, then increased by 0.79% to -$776.9 million in 2023, then fell by 15.03% to -$893.7 million in 2024, then rose by 4.4% to -$854.4 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Enterprise Value are -$854.4 million (Q4 2025), -$952.9 million (Q3 2025), and -$938.9 million (Q2 2025).